Neurogene
NGNE
84 hedge funds and large institutions have $391M invested in Neurogene in 2020 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 16 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
19% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 16
18% more capital invested
Capital invested by funds: $330M → $391M (+$60.7M)
4% more funds holding
Funds holding: 81 → 84 (+3)
0.01% more ownership
Funds ownership: 3.3% → 3.3% (+0.01%)
52% less call options, than puts
Call options by funds: $1.24M | Put options by funds: $2.56M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$7.58M |
| 2 |
BlackRock
New York
|
+$5.43M |
| 3 |
Alkeon Capital Management
New York
|
+$3.67M |
| 4 |
Morgan Stanley
New York
|
+$2.91M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.04M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$4.47M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.87M |
| 4 |
SG Americas Securities
New York
|
-$1.54M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.49M |
NGNE Hedge Fund Activity: Q4 2020 in Review
84 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2020, worth a combined $391M — up 18% from $330M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new NGNE positions and 16 closed out — a net gain of 3 holders — while 28 added to existing stakes and 22 trimmed.
The largest buyer was State Street, adding an estimated $7.58M. The largest seller was EcoR1 Capital, cutting an estimated $9.04M.
- 84 institutional investors held Neurogene (NGNE) as of Q4 2020, up from 81 in Q3 2020.
- Funds reported $391M of Neurogene stock for Q4 2020, up 18% quarter-over-quarter.
- 19 funds opened new Neurogene positions in Q4 2020 and 16 closed out, a net change of +3 holders.
- The largest Neurogene buyer in Q4 2020 was State Street, an estimated $7.58M added.
- The largest Neurogene seller in Q4 2020 was EcoR1 Capital, an estimated $9.04M sold.
Based on aggregated 13F filings for Q4 2020.